Overview

MANP in African Americans With Hypertension

Status:
Recruiting

Trial end date:
2023-06-30

Target enrollment:
0

Participant gender:
All

Summary

Evaluate the cardiovascular properties of MANP in AA with Hypertension

Phase:

Phase 1

Accepts Healthy Volunteers?

Accepts Healthy Volunteers

Details

Lead Sponsor:

Mayo Clinic

Criteria

Inclusion Criteria:

1. Hypertension, defined as a mean supine BP greater than 140/90 mmHg and taking at least
one standard of care therapies (including a diuretic, angiotensin converting enzyme
inhibitor or angiotensin receptor blocker and a calcium channel blocker);

2. MDRD estimated GFR > 30 mL/min to be calculated at the screening visit by available
serum creatinine

3. Male or female African Americans

4. Between the ages of 20 and 70 years;

5. Have a body mass index (BMI) within the range of 18-40 kg/m2;

6. Be able to communicate effectively with the study personnel

7. Be adequately informed of the nature and risks of the study and give written informed
consent prior to receiving study medication.

Exclusion Criteria:

1. Known hypersensitivity or allergy to MANP or other NPs;

2. Women of child bearing age

3. Having received any investigational drug or device within 30 days prior to entry into
the study; 4) A history (within the last 2 years) of alcohol abuse, illicit drug use,
significant mental illness, physical dependence to any opioid, or any history of drug
abuse or addiction;

4. A history of difficulty with donating blood or donated blood or blood products within
45 days prior to enrollment;

5. Clinically significant new illness in the 1 month before screening in the opinion of
the investigator;

6. History of severe allergies;

7. History of CAD, CVD or syncope;

8. History of epilepsy or other seizure disorder;

9. History of organ transplantation;

10. Malignancy within 5 years;

11. Clinically significant intrinsic renal disease, renal artery stenosis, or history of
fibromuscular dysplasia of the renal arteries and;

12. Consumption of a phosphodiesterase-5 inhibitor.

13. Known adrenal insufficiency